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 1 
Case report 
A 65-year-old male was originally diagnosed with prostate cancer in 1995 when prostate 
biopsies revealed adenocarcinoma. Upon radical retropubic prostatectomy, disease was 
determined to be confined to the prostate; pelvic lymph nodes were negative for disease. The 
patient’s serum PSA was subsequently undetectable, and he was lost to follow up for several 
years. In 2002, his PSA was detected at 0.2 ng/ml. The PSA rose to 0.3 ng/ml the following year 
and was detected at 1.9 ng/ml in 2005. In July of 2006, screening showed a PSA of 9.4 ng/ml 
and the following month his PSA had climbed to 10.56 ng/ml. The patient remained 
asymptomatic apart from erectile dysfunction, a common side effect of prostatectomy. He had no 
new areas of bone pain and no new respiratory, gastrointestinal, genitourinary, or neurological 
complaints.   
  CT with contrast of the pelvis and abdomen showed no obvious evidence of metastatic 
disease. Whole body bone scan displayed some osteoarthritic changes, but no definite evidence 
for bony metastatic disease. A ProstaScint whole body image was ordered (Figure 1). Results 
showed a low level of reactivity in the prostate fossa, but less intense than normally seen with 
recurrence. Further, no reactive adenopathy or evidence of bony metastatic disease was apparent. 
However, focal ProstaScint reactivity appeared within the upper lobe of the left lung (Figure 2). 
CT of the chest was ordered for comparison and a spiculated lesion measuring 2.8 cm in 
diameter was identified. The nodular density resembled a primary lung carcinoma, but the lesion 
seemingly correlated with the area of ProstaScint reactivity. Upon biopsy, the tumor was 
determined to be a prostate metastasis. The margins of the excision were negative for disease but 
vascular channel invasion by carcinoma existed. The patient soon began continuous hormonal 
management with Lupron injections as treatment for systemic prostate metastasis.  2 
  In November 2006, a month after biopsy, the patient’s PSA dropped to 2.06 ng/ml. In 
March 2007, his serum PSA was 0.07 ng/ml and in June 2007, 0.16 ng/ml. At this point the 
patient chose to proceed with pulse hormonal therapy. As of September 2007, his PSA had risen 
to 2.19 ng/ml. He continued to experience erectile dysfunction and noted hot flashes attributable 
to the hormonal treatment.  Otherwise he had no symptoms of metastatic prostate cancer. To our 
knowledge, this is the only case report of an isolated pulmonary metastasis of prostate 
adenocarcinoma discovered by ProstaScint. 
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Introduction 
Prostate cancer is the most prevalent cancer in males with a predicted incidence of 
186,320 in 2008. An estimated 28,660 will die in 2008 as a result of prostate cancer, second 
among cancers only to lung malignancies. The lifetime risk of developing prostate cancer is over 
16% (American Cancer Society [ACS], 2008). Because most men who present with prostate 
cancer will be asymptomatic (Miller, Hafez, Stewart, Montie, & Wei, 2003), the American 
Cancer Society (ACS) recommends screening the general population at age fifty with a yearly 
digital rectal exam (DRE) and serum prostate specific antigen (PSA) test (2007). Although 
relatively effective when used together, each technique has its limitations. DRE allows palpation 
of only the posterior aspect of the prostate gland; as such, some nodules can go undetected. 
Additionally, 50% of palpable nodules are benign (Jewett, Bridge, Gray, & Shelley, 1968). An 
elevated PSA raises the suspicion of prostate cancer, but may be secondary to other processes 
like benign prostatic hyperplasia (BPH) or prostatitis (ACS, 2007). While either DRE or PSA 
screenings can be used to estimate a high or low risk for prostate cancer, neither test can 
definitively diagnose or stage it. Accurate staging of the cancer is important in guiding selection 
of treatment options as well as determining prognosis.  
Radical prostatectomy, which involves removal of the gland and nearby lymph nodes, has 
become the most common treatment for localized cancer, with 60,000 procedures being 
performed yearly (Bill-Axelson et al., 2005). The surgery is intended to be curative, and in 
theory, the PSA should drop and remain at undetectable levels. Unfortunately, 27-53% of 
patients will show measurable PSA levels in the blood, known as biochemical recurrence, within 
ten years of surgery (Ohori et al., 1994; Trapasso, deKernion, Smith, & Dorey, 1994). Further, 
15% of patients undergoing radical prostatectomy develop clinical evidence of distant metastasis 4 
within ten years (Bill-Axelson et al.). A rise in the PSA may be due to local recurrence in the 
prostate fossa and/or distant metastases (Lattouf & Saad, 2003). Therefore, identifying the 
presence and location of cancerous tissue is essential in determining a localized or systemic 
treatment regimen. Disease most often spreads to bone and pelvic lymph nodes (Nakamachi et 
al., 2002). As such, CT of the pelvis/abdomen and radionuclide bone scan are commonly used to 
find metastases, but with limited effectiveness (Kane et al., 2003). Activity seen on bone scans is 
not specific to prostate cancer, and CT can only detect lymph nodes enlarged to greater than 
1 cm in diameter.  
While metastases most often present in bone and local lymph nodes, they can occur in 
any tissue and therefore may not appear in the above scans. Specifically, studies suggest 
evidence of metastasis to the lung is found in 46-63% of autopsies on men with prostate cancer 
(Bubendorf et al., 2000; Nakamachi et al., 2002); however, symptomatic presentation of 
pulmonary metastasis is quite uncommon (Fabozzi, Schellhammer, & el-Mahdi, 1995; 
Nakamachi et al.). Lung metastasis with no known bone or lymph node involvement is even less 
likely; a number of such instances have been reported as case studies. Tracking the source of the 
rising PSA can be a difficult task. Without respiratory symptoms, it would be hard to warrant 
imaging of the lungs over any other area of the body.  
Capromab pendetide, trade name ProstaScint, is a murine monoclonal antibody attached 
to an Indium-111 radio-tracer approved by the FDA in 1996. It reacts with a specific protein, 
prostate-specific membrane antigen (PSMA), which is expressed by both normal and cancerous 
prostate epithelial cells. ProstaScint is indicated “as a diagnosing imaging agent in newly 
diagnosed patients with biopsy-proven prostate cancer, thought to be clinically localized after 
standard diagnostic evaluation, who are at high risk for pelvic lymph node metastases, and in 5 
post prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic 
evaluation in whom there is a high clinical suspicion of occult metastatic disease” (Food and 
Drug Administration, Center for Drug Evaluation & Research, 2001) . ProstaScint should not 
replace bone scans for the evaluation of skeletal metastasis as bone scans are more sensitive for 
such lesions. Nor is ProstaScint indicated for screening the general population (Cytogen, 1997). 
In theory, the monoclonal antibody should only react with cells within the prostate gland 
or prostate cancer metastases throughout the body. However, laboratory studies indicate that 
other human cells produce PSMA, suggesting a decreased specificity. Likewise, clinical studies 
have varied in their reports of the sensitivity, specificity, and accuracy of the ProstaScint scan. 
This review summarizes original research and retrospective studies assessing the effectiveness of 
the ProstaScint scan in detecting local recurrence or distant metastasis. Reviewed works have 
been limited to published studies in which patients had been previously treated with curative 
intent, but upon follow-up had reason to suspect treatment failure. Further, only studies 
providing statistical analysis and comparing ProstaScint to histologic confirmation are discussed, 
as biopsy or surgical dissection is regarded as the gold standard for cancer confirmation. A 
number of these studies also described ProstaScint relative to conventional methods of imaging, 
such as CT or MRI. This information is discussed where appropriate; however, as ProstaScint 
hopes to be an improved alternative to these tests, studies using conventional imaging as the 
standard for comparison were not included. Another subset of studies on prostate cancer 
recurrence and metastasis express the effectiveness of ProstaScint scans with respect to patients’ 
reactions to salvage therapy. These works are mentioned, but are not the primary focus of this 
review. Searches were performed in MEDLINE, PubMed, and Science Citation Index, searching 
keywords: prostatic neoplasm, prostate cancer, prostate carcinoma, pulmonary metastasis, lung 6 
metastasis, ProstaScint, and capromab pendetide. References from reviewed articles were traced 
using the same databases. Websites of relevant organizations, such as the Food and Drug 
Administration and the American Cancer Society, were also consulted. 7 
FDA trials 
Clinical trials for FDA approval of ProstaScint assessed the performance of the scan on 
two populations in two separate studies. The first population consisted of newly diagnosed 
patients with tissue confirmation of prostate cancer considered to be at high risk for metastases to 
lymph nodes. These patients underwent ProstaScint immunoscintigraphy prior to staging via 
pelvic lymphadenectomy. The scan demonstrated a 62% sensitivity, 72% specificity, 62% 
positive predictive value (PPV), 72% negative predictive value (NPV), and a 68% overall 
accuracy relative to histological results (Cytogen, 1997). Of greater interest to this review is the 
second population: patients with high clinical suspicion of occult recurrent or residual disease 
following radical prostatectomy. Admission criteria included a PSA >1.0 ng/ml, a negative bone 
scan within eight weeks before the study, and a prostatic fossa biopsy scheduled within eight 
weeks following administration of the monoclonal antibody. The study included patients with a 
PSA ≤1.0 ng/ml only if they had a history of increasing PSA and a DRE suggesting recurrent 
disease. Patients who had received hormonal therapy, chemotherapy, or radiation therapy after 
radical prostatectomy were excluded (Kahn, Williams, Manyak et al., 1998). Of the 181 patients 
with interpretable ProstaScint scans, 158 underwent biopsy. Using tissue confirmation from the 
prostatic fossa as the standard for comparison in the 158 patients, ProstaScint yielded a 49% 
sensitivity, 71% specificity, 50% PPV, 70% NPV, and 63% overall accuracy (Cytogen; Kahn, 
Williams, Manyak et al.).  
The authors admit that the lack of an accurate standard was a crucial limitation in their 
study. A single biopsy of the prostatic fossa served as the standard for comparison. They are 
confident that increased biopsies would have decreased the sampling error and thus revealed a 
significantly higher sensitivity of the scan. Regarding the specificity, researchers point to the 8 
radioactivity of the pubic bone marrow and rectum as incorrectly interpreted prostate fossa 
uptake. They insist that urine within the bladder did not contribute to false positives, as patients 
were catheterized through the duration of the imaging sessions (Kahn, Williams, Manyak et al., 
1998). On another note, this clinical trial did not specifically examine the ability of the scan to 
identify distant metastases. Of the 181 interpretable scans, 76 showed evidence of disease 
beyond the prostatic fossa. Conventional imaging in the form of CT or MRI was performed on 
48 of the 76 patients. This imaging, though, was not part of the study protocol and is not 
representative of the entire population. MRI or CT confirmed 6 extra fossa abnormalities. 
However, only one site outside the prostate bed was biopsied. This limits the ability to compare 
ProstaScint to conventional imaging, as one can not determine if ProstaScint yielded false 
positives or if conventional imaging lacks sensitivity. The researchers do not indicate whether 
patients had achieved PSA remission following prostatectomy, further limiting clinical 
application. Lastly, the ProstaScint scans seem to have been interpreted by a number of nuclear 
medicine physicians at multiple sites. As such, the study has introduced an additional 
confounding variable, in that ProstaScint scans can be difficult to interpret and certain physicians 
may have less skill in doing so (Howell & Hailey, 1999). 
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Efficacy on patients after prostatectomy as primary treatment 
 This section includes two studies (Burgers et al and Kahn et al) that assessed the use of 
the ProstaScint scan on patients with suspicion of occult recurrent or residual disease after 
prostatectomy. The population is similar to that in FDA trial, however the inclusion criteria vary 
with each series.  
Burgers and colleagues (1995) describe a group of men who underwent prostatectomy 
and later presented with suspected residual or recurrent prostate cancer based on increasing PSA 
levels. Patients who had treatment in addition to prostatectomy were excluded from the study. 
Similar to the FDA trial, a PSA >1.0 ng/mL with a life expectancy of more than six months or a 
PSA ≤1.0 ng/mL with a trend of increasing values with a DRE suggestive of residual or recurrent 
disease was necessary for inclusion. This group consisted of 35 patients, 33 of whom showed 
evidence of occult prostate cancer on ProstaScint scan. Prostatic fossa uptake alone was seen in 
11 men, distant metastasis alone was seen in 9 men, and fossa and distant uptake were seen in 12 
men. Notably, the sum of these numbers is 32, not 33. The authors do not offer an explanation 
for this discrepancy. All 35 men in this study underwent biopsy of the prostate bed. The authors 
describe a scan sensitivity of 94%, specificity of 65%, and an overall accuracy of 80% compared 
to the histological results. Further, 20 of the patients also underwent conventional radiological 
imaging in the form of MRI and PET to detect fossa recurrence. Relative to biopsy, these 
methods showed a sensitivity, specificity, and accuracy of 27, 67, and 45% respectively (Burgers 
et al.; Kahn et al., 1994). 
Burgers et al. do not provide information regarding the ages or presenting PSA levels of 
the subjects. Furthermore, the authors do not indicate if patients achieved biochemical remission 
following initial treatment. These inadequacies limit the clinical application of the results. Of 6 10 
false positive ProstaScint scans, Burgers et al feel that biopsy missed the tumor in 3 cases, based 
on positive PET scans and PSA falling in response to radiotherapy. While the study offers 
comparison of MRI and PET to ProstaScint in the prostatic fossa, not all of the participants 
underwent such conventional imaging. This study is also limited by the lack of histological 
confirmation of distant metastasis; only 2 biopsies were attempted in 21 patients with 
extraprostatic fossa antibody uptake. Without histological confirmation, one can not determine if 
ProstaScint yields false positives, or if conventional imaging lacks sensitivity. All patients with 
uptake beyond the fossa received serial CT follow up and at the time of publication, 12 patients 
showed radiological confirmation. This may suggest ProstaScint can detect metastatic lesions 
before they are detectable by more conventional imaging.  
The second study, performed by Kahn et al. (1994), enrolled 27 men with a PSA of 
≥0.8 ng/ml with increasing values on two consecutive evaluations following prostatectomy. 
Patients included were otherwise negative for disease, including negative DRE, bone scan, and 
transrectal ultrasound. Not all patients underwent histological confirmation; a total of 13 men 
had a single TRUS guided biopsy of the prostate fossa performed. Of these 13 men, 11 had 
shown ProstaScint uptake in the fossa, while 2 had negative scans. Each of the 2 negative scans 
correlated with histologically negative specimens. Biopsy confirmed 8 of the 11 positive scans. 
The study also compared PSA values in patients with positive scans versus those with negative 
scans, but found no significant difference (11.8 ng/ml and 4.4 ng/ml, p>.05).  
The biggest limitation in this study is the small sample size, with only 13 subjects 
undergoing histological confirmation. Additionally, single biopsy is used for comparison, 
allowing for sampling error. Given the lack of a perfect standard and the small sample size, the 
authors could not determine sensitivity and specificity values. For the sake of comparison, 11 
sensitivity and specificity were calculated and are included in Table 1. Further, the authors state 
that 18 subjects showed distant uptake of ProstaScint, however, none of these sites were 
biopsied. The authors are specific in stating the images were interpreted by one of two nuclear 
medicine physicians, reducing but not eliminating interreader variability. 
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Efficacy on patients after radiation therapy as primary treatment 
One study (Fang et al) discusses a population of patients initially treated with radiation 
therapy. Subjects were being considered for salvage brachytherapy as a result of biochemical 
failure, defined as three consecutive elevations in their PSA.  
A study by Fang and colleagues (2000) looked at 24 men who had previously received 
radiation therapy as primary treatment. Scans in 21 of the 24 men showed activity in the prostate. 
Biopsy at the prostate guided by ultrasound was performed on 17 of the 24 patients. Several 
patients had multiple prostatic biopsies; if any sample was positive, the biopsy result was 
considered positive. A single pathologist determined 12 biopsies positive. Comparing the results, 
the authors report an overall accuracy of 50%. They calculate a false positive rate of 24% and a 
false negative rate of 67%. In calculating their data, the authors seem to have made assumptions 
regarding scans of 7 patients who did not undergo biopsy. The validity of such data is 
questionable. Likely due to the small sample size, the authors do not report a sensitivity or 
specificity, further limiting one’s ability to compare these results to other studies. The authors 
note that in comparison to studies on postprostatectomy patients, their population more 
frequently showed activity confined to the prostate. They speculate that some false positives may 
have been a result of uptake by normal prostate cells. They additionally state that false positives 
likely resulted from sampling error, as most patients had only one biopsy. Further, the lack of 
control over the number of biopsies compromises the validity of the results. Based on the data, 
the authors feel further treatment plans should not be based on ProstaScint results alone, and that 
rebiopsy of the prostate should continue to be the gold standard for assessment after radiation 
therapy. They suggest that the more useful aspect of the scan may be in identifying extraprostatic 
disease.  13 
Efficacy on patients after varying forms of primary treatment 
The three studies (Elgamal et al, Bermejo et al, and Haseman et al) assess ProstaScint 
scan usage in patients who have undergone treatment with curative intent, but later had reason 
to suspect recurrence or residual disease. That is, the populations in each study are not limited 
to one form of treatment for prostate cancer recurrence.  
Elgamal, Tryochak, and Murphy (1998) analyzed 136 scans of 100 patients. All patients 
had been histologically diagnosed with prostate cancer and treated with curative intent with 
radical prostatectomy, radiation, and/or hormonal therapy. Most patients had been referred 
following PSA failure. However, 3 patients were included “with poor pathologic prognostic 
features.” The authors do not define these features or indicate why these 3 patients were included 
without PSA failure. ProstaScint uptake was evident in 124 of the scans. A total of 7 lymph 
nodes and 26 prostate/prostatic fossa biopsies served as a standard for comparison. Comparing 
these findings gave a sensitivity of 89%, a specificity of 67%, PPV of 89%, and an accuracy of 
89%. Each of 20 positive prostatic biopsies showed corresponding reactivity on the ProstaScint 
scan. There were 6 negative prostatic biopsies; 2 of these patients had shown ProstaScint uptake 
at the prostate/prostatic fossa. All 7 lymph node biopsies were positive; 4 correlated with 
ProstaScint uptake while 3 did not. Due to the small number of negative biopsies, the authors 
could not calculate the negative predictive value. Having only 2 false positive 
immunoscintigraphy results perhaps speaks to the accuracy of the biopsies performed. 
ProstaScint detected 57% of bone lesions visible on bone scan. While bone scan is not specific, 
the difference suggests a limited role of ProstaScint in detecting bony metastasis of prostate 
cancer. Further, the data again indicate a greater percentage of “local recurrence only” in patients 
with an intact prostate compared to those presenting postprostatectomy. 14 
While the study included 100 patients, only 33 were biopsied, leaving a relatively small 
sample size. Additionally, the authors do not specifically define treatment failure in the inclusion 
criteria. Another limitation exists as 34 patients had repeat scans. While it is not clear if any of 
these patients were biopsied, the duplication potentially influences the statistical analysis. 
Furthermore, the statistical analysis combines data from distant and local biopsy sites. However, 
the effectiveness of the scan may vary by site. In addition, 3 lymph node biopsies were 
performed on patients with a negative ProstaScint scan. It is not clear what prompted these 
lymph node biopsies or how the sites for biopsy were determined on such patients. The study 
protocol did not call for other soft tissue imaging (only 7 patients underwent CT or MRI), 
limiting comparison to ProstaScint scans and conventional detection methods. On another note, 
the authors indicate that patients with positive ProstaScint scans had a significantly higher mean 
serum PSA than those with negative ProstaScint scans (61.3 ng/ml and 0.9 ng/ml, p <0.01). 
Similarly, patients with extrapelvic involvement on ProstaScint scan tended to have higher serum 
PSA than those with pelvic uptake only (104.6 ng/ml and 36.3 ng/ml, p=0.03). However, the 
range of serum PSA spans 0.0-2185 ng/ml, with a mean of 55.9 ng/ml and a median of 
4.5 ng/ml. The authors fail to comment on what seems to be at least one outlier and how this 
affects the correlation.  
A study by Bermejo and colleagues (2003) included patients who had undergone a 
ProstaScint scan and surgical exploration/biopsy confirmation of metastatic or recurrent disease 
following definitive treatment. A mail survey to 60 urologic oncologists collected information on 
31 patients with 43 sites of investigation. Some sites were within the prostate fossa while others 
were distant metastases. According to the authors, analyzing the data by site of biopsy yield a 
sensitivity of 94%, specificity of 42%, PPV of 53%, NPV of 92%, and overall accuracy of 65%. 15 
The authors also performed statistical analysis with regards to each patient, finding a sensitivity, 
specificity, PPV, NPV, and overall accuracy of 100, 33, 62, 100, and 68% respectively. Only 
analyses by site of biopsy are included in Table 1.  
The design of the study limits the reliability of the results given the inherent bias and lack 
of control in a mail survey. Further, the type of treatment received by each patient is not 
included, nor is the method of histologic confirmation (biopsy vs. dissection). Additionally, sites 
of uptake on the ProstaScint scan do not necessarily correlate with sites of pathological analysis, 
and not all sites of uptake were biopsied. In performing statistical analysis with regards to each 
patient, those with ProstaScint scans showing uptake anywhere and pathologic confirmation of 
any site were considered true positives. That is, the location of positive biopsy need not 
necessarily be a site of ProstaScint uptake for the scan results to have been considered accurate. 
The design of the study and the methods of statistical analysis severely limit the value of the 
data. 
In another study, Haseman and colleagues (1996) reported on 14 patients, 10 of whom 
had undergone radical prostatectomy and 4 of whom had radiation therapy as primary treatment 
for prostate adenocarcinoma. Patients with prior chemotherapy or hormonal treatment were 
excluded. Inclusion criteria stated patients needed a PSA >1.0 ng/ml or a positive DRE, a 
negative bone scan, and a biopsy of the prostate bed scheduled within eight weeks of the 
ProstaScint scan. Biopsies were performed regardless of scan results. Biopsies were guided by 
ultrasound or DRE findings if abnormalities were evident. Compared to histological findings, 
ProstaScint yielded a sensitivity of 86%, specificity of 43%, PPV of 60%, NPV of 75%, and 
accuracy of 64%. In addition, PET scan was performed on 10 of the patients. Compared to 
histological findings, PET showed a sensitivity of 17%, specificity of 50%, PPV of 33%, NPV of 16 
29%, and accuracy of 30%. The authors believe that there were 3 false negative biopsies, based 
on ProstaScint and PET correlation or response to treatment. Lymph nodes showed ProstaScint 
uptake in 8 of the 14 patients. However, none of the extraprostatic sites correlated with PET or 
CT findings, and therefore were unable to be biopsied.  
The small population size limits the power of the findings. In addition, combining 
postprostatectomy patients with patients who had undergone radiation therapy limits the 
application of the findings. As suggested earlier, recurrence patterns may differ secondary to 
mode of curative therapy (Fang et al., 2000). Haseman et al. offer a second set of data, based on 
an assumption that 3 biopsies were falsely negative. As there was no histologic backing for these 
assumptions, the second set of data has not been included here. This study offers no histologic 
confirmation of lymph nodes positive on ProstaScint scans. The comparison of ProstaScint to 
PET imaging in this study is useful, however not all patients underwent PET and as such the data 
do not represent the entire population. No comparison is drawn to CT scans, though it seems a 
number of patients may have undergone such imaging. 17 
Efficacy inferred from response to salvage radiotherapy 
Studies discussed here express the effectiveness of ProstaScint scans with respect to 
patient’s reaction to salvage therapy. That is, there is no histological confirmation of metastatic 
lesions. Efficacy of the scan is inferred from patient response to salvage radiotherapy for 
suspected recurrence or residual disease. 
A retrospective study by Kahn, Williams, Haseman, and colleagues (1998) looked at 32 
postprostatectomy patients with PSA failure ≥0.4 ng/ml and no other evidence of prostate cancer. 
Patients underwent salvage radiotherapy to the pelvis after a ProstaScint scan; the decision for 
treatment, however, was not based on immunoscintigraphy results. Of the 32 patients, 21 
experienced an initial complete response, defined as a PSA ≤0.3 ng/ml and remaining there for 
thirty days. Of those, 18 maintained a durable complete response, that is a serum PSA remaining 
at or below 0.3 mg/ml for at least six months before the final follow-up. As this was a 
retrospective study, the final follow-up varied by patient. Comparing treatment response to scan 
results, the authors determined that 70% of men with normal scans or scans positive only in the 
prostate fossa had a durable complete response to salvage radiotherapy. Contrarily, only 22% of 
patients with antibody reactivity beyond the prostate fossa achieved durable complete response. 
A three-year follow-up on these patients showed similar results (Kahn, Austin, & Miller, 1999). 
This significant difference (p=0.0225) between treatment response in patients with uptake 
beyond the pelvis and those with normal scans or uptake in the prostatic fossa only suggests that 
ProstaScint scan can help predict a patient’s response to salvage radiotherapy of the pelvis. 
Additionally, no other variable measured showed significant correlation with achieving a durable 
complete response, including pretreatment PSA (p=0.13), pathologic stage (p=0.87), and positive 
prostate biopsy (p=0.96) (Kahn, Williams, Haseman, et al.). 18 
Some series on postprostatectomy patients demonstrate similar findings. Levesque et al. 
(1998) described 13 men with rising PSA who received radiation regardless of their scan results. 
A PSA dropping to and remaining ≤0.2 ng/mL was considered a good response. Of 6 patients 
that had monoclonal antibody uptake beyond the field of radiation, only 2 showed a good 
response. In those patients without ProstaScint reactivity beyond the radiation field, 5 of 7 were 
responders. Similarly, Proaño et al. (2006) found that patients with a negative ProstaScint scan 
prior to radiation had a lower rate of PSA progression following salvage radiotherapy than 
patients with positive scans. 
However, the literature varies on the predictive value of ProstaScint results on PSA 
response to salvage radiotherapy. In a study of 58 men receiving local radiotherapy for rising 
PSA, 20 experienced biochemical relapse after treatment. Nagda et al. (2007) saw no correlation 
(p=0.51) between ProstaScint results and biochemical relapse after radiation, defined as 
PSA >0.2 ng/ml or an increase to greater than the nadir PSA. Moreover, a pre-radiation PSA 
below 1.0 ng/mL seemed the only indicator of decreased biochemical relapse. Notably, the 
median follow-up was 41 months following onset of radiotherapy, much longer than other 
studies of its kind. Similarly, a retrospective study by Thomas and colleagues (2003) found no 
difference in positive or negative scans in the prediction of biochemical response to salvage 
radiotherapy for PSA failure after prostatectomy. However, only 5 patients in their study showed 
ProstaScint uptake beyond the prostate fossa, limiting the power of the findings.  19 
Conclusion 
As evidenced above, the effectiveness of the ProstaScint scan has varied amongst clinical 
studies. Most studies reviewed indicate the scan has a respectable sensitivity but lacks 
specificity. Interestingly, the opposite was true in the FDA trial performed by Kahn, Williams, 
and Manyak et al. (1998), as the scan showed a decent specificity but the sensitivity was lacking. 
This study indeed has a much greater population size. However, with the exception of the study 
by Bermejo et al., the designs of the other studies are relatively similar. The differences in results 
are most likely due to random error resulting from a number of factors influencing the statistical 
calculations. Foremost is the lack of a perfect standard. While histologic confirmation via biopsy 
offers high specificity, its sensitivity is limited by sampling error. Data suggest that 20% of 
prostate carcinoma may be missed on initial biopsies (Ellis & Brawer, 1995). Furthermore, 
ProstaScint scans can be difficult to interpret and readings may vary by radiologist (Howell & 
Hailey, 1999). As such, a confounding variable exists between all studies discussed. On another 
note, small tumor volume and inadequate uptake or distribution of the monoclonal antibody may 
result in false negative scans. Additionally, prostate specific membrane antigen (PSMA) 
expression has been seen in variety of tissue samples. Samples of normal tissue from prostate, 
bladder, kidney, testis, ovary, fallopian tube, breast, sweat glands, adrenal gland, liver, 
esophagus, stomach, duodenum, colon, heart, skeletal muscle, and brain have shown ProstaScint 
uptake (Kinoshita et al., 2006; Lopes, Davis, Rosenstraus, Uveges, & Gilman, 1990; Silver, 
Pellicer, Fair, Heston, & Cordon-Cardo, 1997). Samples of cancerous tissue from bladder, 
kidney, testis, esophagus, stomach, small intestine, colon, adrenal gland, and lung have also 
expressed the protein (Kinoshita et al.). Expression of PSMA in other tissues may decrease scan 20 
specificity. Conversely, some lines of prostate cancer do not express PSMA, potentially 
decreasing scan sensitivity (Israeli, Powell, Corr, Fair, & Heston, 1994).  
Despite inconsistent results, the ProstaScint scan does offer clinicians an additional tool 
to assist in treatment planning for patients with prostate cancer. However, as with any medical 
test, the potential benefit of the scan must be weighed against its negative side effects and 
financial cost. According to the package insert, adverse side effects of ProstaScint infusion were 
seen in 4% of patients (Cytogen, 1997). Most common reactions included hypotension, 
hypertension, elevated bilirubin, and elevated liver enzymes. Less often, itching, stinging at 
infusion site, fever, chills, headache, myalgia, chest pain, and shortness of breath have been seen. 
No deaths have been attributed to ProstaScint administration. In addition, as the monoclonal 
antibody is a foreign protein developed from mice, patients can develop a response known as 
human anti-mouse antibody (HAMA). This response, while uncommon, could change the 
efficacy of future murine-based diagnostic and therapeutic procedures as well as increase the risk 
of adverse reactions (Cytogen; Howell & Hailey, 1999). While relatively safe, a ProstaScint scan 
costs an estimated $2500 and may not be a cost-effective option for all patients (Howell & 
Hailey).  
The role of ProstaScint in the post treatment population is to aid in finding the cause of a 
rising PSA. It is not indicated for screening or assessment of response to treatment. It is unclear 
if ProstaScint results can help predict a patient’s response to salvage radiotherapy. While 
ProstaScint seems to be more effective in detecting residual or recurrent disease than CT, MRI, 
or PET, the literature is lacking in direct comparisons of these more conventional imaging 
studies and ProstaScint to biopsy confirmation. Currently, the data regarding the efficacy of 
ProstaScint do not provide convincing evidence such that clinicians can comfortably trust its 21 
findings. Given the metastatic patterns of prostate cancer, ProstaScint scan should only be 
considered after bone scan and CT of the pelvis/abdomen have been ineffective in guiding 
treatment. As no study indicates treatment plans should be determined solely on findings of a 
ProstaScint scan, using these conventional tests first may be a more cost effective approach to 
guiding treatment. However, as with our patient, the ProstaScint scan can be invaluable in those 
without evidence of disease on such conventional scans. More convincing data showing 
histologic confirmation of distant metastasis are necessary to fully appreciate the usefulness of 
the ProstaScint scan. However, distant biopsies can be difficult to perform and invasive. 
Clinicians would benefit from long term follow up of sites unable to be initially confirmed by 
biopsy. Recently, ProstaScint scans have been combined with CT or MRI images in a technique 
called ProstaScint Fusion imaging (Kipper, 2003). This method hopes to enhance the detection 
of metastatic disease, but evidence of the effectiveness is currently limited. Future research 
should also assess the effectiveness of ProstaScint scan compared to conventional imaging at 
identifying distant metastatic lesions on large populations. 
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Table 1 
Outcomes Comparison for ProstaScint Studies, in the Order Discussed in this Project 
Study  n  Sensitivity Specificity  PPV NPV Accuracy 
False (+) 
rate 
False (-) 
rate 
Kahn, Williams, Manyak et al., 1998 158  49 71  50  70  63    
Burgers, Hinkle, & Haseman, 1995  35  94  65      80     
Kahn et al., 1994  13  100*  40*           
Fang et al., 2000  17          50  24  67 
Elgamal, Troychak, & Murphy, 1998  33  89  67  89    89     
Bermejo, Coursey, Basler, Austenfeld, & 
Thompson, 2003  41  94  42  53  92  65     
Haseman, Reed, & Rosenthal, 1996  14  86  43  60  75  64     
 
 
n indicates the number of confirmatory biopsies performed. That is, some patients in some series had more than one site biopsied. 
* Kahn et al., 1994 did not calculate the sensitivity or specificity. These calculations have been made for the sake of comparison. 
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Figure 1: Full body ProstaScint scan of the patient.  
  29 
Figure 2: ProstaScint scan of patient’s chest. Isolated lung metastasis marked.  
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Abstract 
 
Objective. ProstaScint is a monoclonal antibody that reacts with a protein expressed by prostate 
epithelial cells. ProstaScint should only react with normal or malignant prostate cells throughout 
the body. However, studies have shown varied sensitivities, specificities, and accuracies. We 
summarize studies on ProstaScint’s effectiveness at detecting local recurrence or distant 
metastasis. A case report is also described. Methods. The review includes articles found through 
MEDLINE, PubMed, and Science Citation Index that compare ProstaScint to histologic 
confirmation in patients with suspicion of treatment failure. Results. The effectiveness of 
ProstaScint varied amongst clinical studies; however most describe respectable sensitivity with 
low specificity. Conclusion. ProstaScint is an additional tool to aid treatment planning for 
patients with recurrent prostate cancer. ProstaScint should be considered after bone scan and 
pelvic/abdominal CT have been ineffective in guiding treatment. More convincing data showing 
histologic confirmation of distant metastasis are necessary to fully appreciate ProstaScint’s 
usefulness.  
 
 
 